{"id":"W2793495237","doi":"10.1158/1538-7445.sabcs17-pd6-10","title":"Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Cohort; Triple-negative breast cancer; Clinical endpoint; Breast cancer; Metastatic breast cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001729619,0.0008561947,0.0007540144,0.0003949836,0.0007827231,0.001175926,0.0008184208,0.0008721802,0.01192228],"category_scores_gemma":[0.001254978,0.0003591889,0.0008745302,0.0003530897,0.0004015032,0.0007775642,0.0006013145,0.002527142,0.002339094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001141004,"about_ca_system_score_gemma":0.002234197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001863865,"about_ca_topic_score_gemma":0.003359603,"domain_scores_codex":[0.9995334,0.0001673386,0.00004635158,0.0001062333,0.00007658762,0.00007002665],"domain_scores_gemma":[0.9990184,0.00009039642,0.0001807533,0.0001169315,0.0001316784,0.0004617359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6277624,0.03445582,0.05441257,0.001907797,0.003241297,0.0006423609,0.0002962675,0.002210589,0.03924959,0.001234705,0.08535836,0.1492282],"study_design_scores_gemma":[0.4893827,0.2677535,0.1047858,0.0006039379,0.002667432,0.002276726,0.0002922631,0.002729772,0.01756609,0.001639209,0.1101885,0.000114027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8881398,0.004861817,0.003348863,0.001639129,0.0004185218,0.01498506,0.06926497,0.0002773993,0.01706456],"genre_scores_gemma":[0.9028428,0.002087358,0.006037071,0.003541063,0.0003689172,0.01220648,0.06057956,0.00009813086,0.01223847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01192228,"threshold_uncertainty_score":0.03988397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0679343402304146,"score_gpt":0.4227587382644817,"score_spread":0.3548243980340671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}